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ABSTRACT		Cost-benefit	analysis	can	be	used	to	quantify	the	value	of	clinical	pharmacy	services.	Providing	Effective	Therapy	and	Minimum	cost,	Quantify	costs	of	care,	Quantify	outcomes,	Assess	whether	and	by	how	much	average	costs	and	outcomes	differ	among	treatment	groups,	Compare	magnitude	of	difference	in	costs	and	outcomes	and	evaluate	“value	 for	costs”	by	reporting	a	cost-effectiveness	ratio,	net	monetary	benefit,	or	probability	that	ratio	is	acceptable	–	Potential	hypothesis:	Cost	per	quality-adjusted	life	year	saved	signifi-cantly	less	than	Rs.75,000,	To	Perform	sensitivity	analysis.	For	providing	good	effective	therapy	with	less	adverse	drug	reaction	at	affordable	price,	Cost-Identification,	Cost-Effectiveness	Analysis,	Cost-Utility	Anal-ysis,	Cost-Benefit	Analysis,	Clinical	outcomes:	Cure,	comfort	and	survival,	Humanistic	outcomes:	Physical,	emotional,	social	function,	role	performance,	Economic	outcomes,	Economic	Evaluation,	Cost	of	Illness	Eval-uation	(COI),	Cost	Benefit	Analysis	(CBA),	Cost	Minimization	Analysis,	Cost	Effective	Analysis:	Cost	Utility	Analysis.	
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INTRODUCTION	A	Pharmacoeconomics	study	evaluates	 the	cost	and	effects	(expressed	in	terms	of	monetary	value,	effec-tiveness,	 efficacy	 or	 enhanced	 quality	 of	 life)	 of	 a	pharmaceutical	 product.[1]	 It	 identifies,	 measures,	and	 compares	 the	 costs	 and	 consequences	 of	 drug	therapy	 to	 healthcare	 systems	 and	 society.	 Phar-macoeconomics	 research	 in	 the	managed	 care	 con-solidation	 to	diversification.	Health	Economics,	 as	a	
branch	of	economics	is	itself	relatively	young[3].	Basi-cally	the	pharmacoeconomics	is	needful	in	following	manner;		•	In	Industry:	Deciding	among	specific	research	and	development	alternatives.		•	In	Government:	Determining	program	benefits	and	prices	paid.		•	In	Private	Sector:	Designing	insurance	benefit	cov-erage.	The	direct	medical	costs	contain	the	hospitalization,	outpatient	 visits	 (to	 primary	 care	 providers	 and	 to	specialists),	procedures	and	tests	(blood	analysis,	ul-trasound	scans,	 surgical	 interventions),	medical	de-vices,	home	care,	nursing	care	and	medications.	The	direct	 nonmedical	 costs	 comprise	 the	 transporta-tions,	 nonmedical	 services	 (home	 helper,	 meals	 on	wheels,	social	assistance),	devices	and	investments	or	the	informal	care.	 The	 indirect	 costs	 are	 mostly	 mean	 the	 sick	leave	 or	 absences,	 reduced	 productivity	 at	 work,	early	 retirement	 due	 to	 illness	 and	 the	 premature	death[13].	
Cost-minimization	analysis	(CMA)	Cost-minimization	or	cost-identification	is	an	analyt-ical	process	used	in	pharmacoeconomics	to	examine	the	cost	of	drug	treatment	when	the	clinical	effective-ness	of	the	alternative	therapies	is	identical.	
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Cost-effectiveness	(CEA)	and	cost-utility	analysis	
(CUA)	The	professional	literature	distinguishes	two	analysis	methods,	where	the	costs	and	the	utilities	or	benefits	–	opposite	to	the	cost-benefit	analysis	–	measured	in	different	units:	these	are	the	cost-effectiveness	(CEA)	and	the	cost-utility	analysis	(CUA).	As	long	as	at	the	former	method	the	outcomes	are	measured	in	some	clinical	characteristics,	at	the	CUA	the	outcomes	are	expressed	 in	 special	 units,	 in	 quality	 adjusted	 life	years	(QALY),	while	the	costs	are	calculated	in	mone-tary	units.	According	to	Wonderling[28]	cost-effective-ness	analysis	(CEA)	is	an	economical	or	management	tool	for	evaluating	which	therapy	are	the	most	cost-effective,	so	how	to	achieve	greater	effect	next	to	un-changed	 expenditures	 or	 lower	 costs	 next	 to	 un-changed	 effects.	 The	 expansion	 in	 use	 of	 economic	evaluation	by	health	agencies	has	mirrored	the	grow-ing	 recognition	 of	 the	 usefulness	 of	 health-related	quality	 of	 life	 (HrQoL)	 as	 an	 important	 indicator	 of	outcome	of	disease	 treatment	among	clinicians	and	patients	[21].	Like	 the	 CMA	 in	micro	 level	 the	 application	 of	 CEA	could	show	in	the	following	example:	there	are	four	therapies,	 which	 treated	 the	 same	 type	 of	 disease	(providing	the	comparability	of	 their	costs)	and	the	effects	are	measured	in	quality	of	life	generally.	
Cost-benefit	analysis	(CBA)	According	 to	David[71]	 the	 cost-benefit	 analysis	 is	 a	technique	that	is	used	to	determine	options	that	pro-vide	the	best	approach	for	the	adoption	and	practice	in	terms	of	benefits	in	labour,	time	and	cost	savings.	Like	the	CEA	and	CUA,	the	CBA	also	compare	the	costs	and	the	benefits	but	those	are	expressed	in	the	same	monetary	units	–	as	the	health	project	forming	part	of	government	policy	may	take	several	years,	so	in	the	CBA	the	time	value	of	money	take	part	too.	The	com-mon	basis	can	provide	the	comparability:	this	is	the	net	 present	 value[32].	 Cost–benefit	 analysis,	 which	used	 by	 institutions	 those	 operate	 the	 total	 health	system,	can	influence	a	health	policy	of	government	so	this	analysis	used	rather	in	macro	level.	Therefore,	the	applied	discount	rate	we	should	assume	that	the	examined	health	projects	are	occurred	in	the	same	in-terest	rate	environment	and	because	of	the	depend-ence	of	method	from	the	net	present	value	–	so	from	the	 time	 value	 of	money	 –	 the	 duration	 of	 projects	should	also	be	identical.	
Consequences[38-42]	According	to	our	current	knowledge	there	are	three	different	analysis	methods	used	 in	 the	health	econ-omy:	the	cost-	minimization,	the	cost-effectiveness	–	inside	 of	 this	 the	 cost-utility	 –	 and	 the	 cost-benefit	analysis.	 Application	 of	 all	 three	methods	 has	 diffi-culty	because	of	the	effects	or	benefits	of	therapies	or	health	projects	are	estimated	hardly.	Therefore,	it	can	determine	that	these	methods	apply	effectively	when	
the	compared	therapies	treated	the	same	type	of	dis-eases,	the	main	health,	financial	and	other	economic	factors	 those	 can	 impact	 to	 the	 valuation	 consider	equivalent,	so	these	are	realized	under	the	same	mac-roeconomic	conditions,	finally	all	information	should	be	available	for	the	estimation.	However	experts	for-mulated	several	critics	against	the,	in	micro	level	the	cost-utility	 analysis	 is	 advisable	 to	 apply,	 since	 in	macro	level	the	use	of	cost-benefit	analysis	can	con-tribute	mostly	to	the	better	operation	of	health	sup-ply	system.	
MATERIAL	
Selection	of	a	Survey	Frame:	The	survey	frame	pro-vides	 the	 means	 of	 identifying	 and	 contacting	 the	units	 of	 the	 survey	 population.	 The	 frame	 is	 in	 the	form	of	a	list,	for	example.	
• Number	of	TB	research	Centre	
• Route	Design	
• OPD	Timing	
• Questions	of	Survey	
• Collecting	the	Data	of	Clinical	Survey	
Questionnaire	Design:	A	questionnaire	(or	form)	is	a	group	or	sequence	of	questions	designed	to	obtain	information	on	a	subject	from	a	respondent.		
Clinical	survey	1.	How	many	TB	patients	visit	to	the	hospital	per	day?	2.	Which	type	of	TB	they	suffer?	3.	Which	drug	is	most	prescribed	by	you?		4.	Which	brand	drugs	shows	good	effectives?	
Market	Survey	1.	Which	medicine	/Brand	frequently	prescribed	by	your	Doctor?	2.	What	Drug	shows	good	efficacy?	3.	How	many	brands	you	have?	What	is	the	cost	vari-ation?	4.	Which	brand	is	most	selling?	5.	Substitute	of	this	brand?	What	are	the	generic	op-tions	available	in	this	combination?	
Data	 Collection:	 Data	 collection	 is	 the	 process	 of	gathering	the	required	information	for	each	selected	unit	in	the	survey.		
METHODS	
Clinical	 Survey[10]:	Clinical	 study	design	 is	 the	 for-mulation	of	trials	and	experiments,	as	well	as	obser-vational	studies	in	medical,	clinical	and	other	types	of	research	(e.g.,	epidemiological)	involving	human	be-ings.	It	involves	Communicating,	Understanding,	note	down	&	analyzing.	Communicating–	To	a	large	extent,	having	 a	 High	 IQ	makes	 communications	 more	 so-phisticated	for	better	or	worse	–	and	increases	the	de-
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sire	to	participate	actively.	Understanding	–	What	ex-actly	Physician	want	to	say.	Note	down	&	analyzing	–	Collect	the	information	what	Physician	share	&	ana-lyzing	that.		
Finding	a	Good	Doctor	–	If	you	can	find	a	compatible	doctor,	 it’s	a	great	foundation.	Trust	and	good	com-munications	are	essential.	if	you	can	find	a	compati-ble	doctor,	 it’s	a	great	 foundation.	Trust,	mutual	re-spect	and	tactful	communications	are	essential.	It	 is	important	to	be	realistic	about	the	situation	and	what	is	possible.	Both	the	patient	and	the	doctor	have	lim-ited	time	and	energy,	so	stay	focused	on	the	most	im-portant	aspects.	Then	persist	until	you	are	both	clear	about	what	is	happening	and	what	you	are	going	to	do.	Prepare	for	consultations,	make	written	notes	and	take	care	of	your	own	health.	
Market	Survey[53]	
• Retail	outlet	in	TB	center	and	Outside	the	Tb	center	
• Retail	Survey	
• Questions	to	retailer,	collecting	retailer	data	
Condition	for	good	survey		
Suitability	survey	method	
• Targeted	TB	hospital		
• Demand	of	product	
• Physician	faith	on	brand/drug	
• Reliable	brand	as	well	as	low	cost	brands		
Efficient	method	for	research	
• Low	cost	
• Rapid	action		
• Good	stability	
Steps	of	a	Survey	It	may	 appear	 that	 conducting	 a	 survey	 is	 a	 simple	procedure	of	asking	questions	and	then	compiling	the	answers	 to	 produce	 statistics.	 However,	 a	 survey	must	 be	 carried	 out	 step	 by	 step,	 following	 precise	procedures	and	formulas,	if	the	results	are	to	yield	ac-curate	and	meaningful	information.		
The	steps	of	a	survey	are		
• Formulation	of	the	Statement	of	Objectives	
• Selection	of	a	survey	frame	
• Questionnaire	design	
• Data	collection	
• Data	capture	and	coding	
• Estimation	
• Data	analysis	
• Documentation.	
Formulation	of	the	Statement	of	Objectives	One	of	the	most	important	tasks	in	a	survey	is	to	for-mulate	the	Statement	of	Objectives.	This	establishes	not	 only	 the	 survey’s	 broad	 information	 needs,	 but	the	 operational	 definitions	 to	 be	 used,	 the	 specific	topics	to	be	addressed	and	the	analysis	plan.		
Data	Capture	and	Coding		After	the	data	are	collected,	they	are	coded	and,	if	a	computer-assisted	 collection	method	was	 not	 used,	captured.	Coding	is	the	process	of	assigning	a	numer-ical	value	to	responses	to	facilitate	data	capture	and	processing	in	general.		
Estimation		Once	the	data	have	been	collected,	captured,	coded,	the	next	step	is	estimation.	Estimation	is	the	means	by	which	the	statistical	agency	obtains	values	for	the	population	of	interest	so	that	it	can	draw	conclusions	about	that	population	based	on	information	gathered	from	 only	 a	 sample	 of	 the	 population.	 An	 estimate	may	be	a	total,	mean,	ratio,	percentage,	etc.	
Data	Analysis	Data	analysis	involves	summarizing	the	data	and	in-terpreting	their	meaning	in	a	way	that	provides	clear	answers	to	questions	that	 initiated	the	survey.	Data	analysis	should	relate	the	survey	results	to	the	ques-tions	and	issues	identified	by	the	Statement	of	Objec-tives.	 It	 is	one	of	 the	most	crucial	 steps	of	a	 survey	since	the	quality	of	the	analysis	can	substantially	af-fect	the	usefulness	of	the	whole	survey.		
Documentation	Documentation	provides	a	record	of	the	survey	and	should	encompass	every	survey	step	and	every	sur-vey	phase.	It	may	record	different	aspects	of	the	sur-vey	and	be	aimed	at	different	groups,	such	as	man-agement,	 technical	 staff,	 designers	 of	 other	 surveys	and	users.	For	example,	a	report	on	data	quality	pro-vides	users	a	context	for	informed	use	of	the	data.	A	survey	report	that	 includes	not	only	what	decisions	were	made,	but	also	why	 they	were	made	provides	management	 and	 technical	 staff	 with	 useful	 infor-mation	for	 future	development	and	 implementation	of	similar	surveys.	During	implementation,	documen-tation	of	procedures	for	staff	helps	to	ensure	effective	implementation.	
RESULT	AND	DISCUSSION	
Hospital	name:	Govt.	TB	treatment	unit	(UPSC)	
Address:	Charminar,	Hyderabad.	
Doctor	name:	Dr.	Hema	Bindu	
OPD	timing:	10am-2pm	
Sno. Answer Conclusion Adr’s 
1 15-18 
Rifampicin is 
Prescribed 
Head-
ache, 
Stomach 
upset 
Nausea 
2 Pulmonary TB 
3 
INH, Rifam-
picin, Ethambu-
tol 
4 Lupin Ltd 
Hospital	 name:	 Princess	 Esra	 Hospital	 (Owaisi	Group	of	Hospital)	
Address:	Mughalpura,	Charminar	
Doctor	name:	Dr.	Aleemuddin	Naveed		
OPD	timing:	9am-1pm	
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Sno. Answer Conclusion Adr’s 
1 7-10 
Rifampicin is 
Prescribed 
Head-
ache, 
Stomach 
upset 
Nausea 
2 Extra pulmo-nary 
3 
INH, Rifam-
picin, Ethambu-
tol 
4 Lupin Ltd 
Hospital	name:	Osmania	General	Hospital		
Address:	Afzal	gaunj,	Hyderabad	
Doctor	name:	Dr.	Dorai	raja	David		
OPD	timing:	9:30am-1pm	
Sno. Answer Conclusion Adr’s 
1 150-200 
Rifampicin 
is prescribed 
Headache, 
Stomach 
upset 
Nausea 
2 Pulmonary, ex-
tra pulmonary 
3 Rifampicin, 
Ethambutol, 
Pyrazinamide, 
INH 
4 Lupin 
Hospital	name:	Govt.	TB	Treatment	Unit	
Address:	Dabeerpura,	Hyderabad	
Doctor	name:	Dr.	Anuradha		
OPD	timing:	9am-12:30pm		
Sno. Answer Conclusion Adr’s 
1 100-110 
Rifampicin 
is prescribed 
Headache, 
Stomach 
upset 
Nausea 
2 Pulmonary, ex-
tra pulmonary 
3 Rifampicin, 
Ethambutol, 
pyrazinamide, 
INH 
4 Sun Pharma 
Hospital	name:	Princess	Durrushevar	Childrens	and	General	Hospital	
Address:	Purani	Haveli,	Hyderabad	
Doctor	name:	Dr.	Ajaz	
OPD	timing:	10am-	11am	
Sno. Answer Conclusion Adr’s 
1 3-6 
Rifampicin 
is prescribed 
Headache, 
Stomach 
upset 
Nausea 
2 Pulmonary TB 
3 Rifampicin, 
ethambutol, 
INH 
4 Sun Pharma 
Hospital	name:	Mahavir	Hospital	&	Reaserch	Hospi-tal	
Address:	Masab	tank,	Hyderabad	
Doctor	name:	Dr.	Sohaib	Ansary	
OPD	timing:	10am-11am	
Sno. Answer Conclusion Adr’s 
1 10-15 
Rifampicin 
is prescribed 
Headache, 
Stomach 
upset 
Nausea 
2 Pulmonary,  
3 Rifampicin, 
Ethambutol, 
Pyrazinamide, 
INH 
4 Themes.pharma 
Hospital	name:	Star	Hospital	
Address:	Banjara	Hills,	Road	No-10,	Hyderabad	
Doctor	name:	Dr.	Anuradha	T	
OPD	timing:	1pm-4pm	
Sno. Answer Conclusion Adr’s 
1 10-20 
Rifampicin 
is prescribed 
Headache, 
Stomach 
upset 
Nausea 
2 Pulmonary, Ex-
tra pulmo-nary 
3 Rifampicin, 
ethambutol, py-
razinamide INH 
4 Themes.pharma 
Hospital	name:	Alpha	Super	speciality	hospital	
Address:	Mughalpura,	Hyd	
Doctor	name:	Dr.	Nishath	
OPD	timing:	11am	-2pm	
Sno. Answer Conclusion Adr’s 
1. 20-30 
Rifampicin 
is pre-
scribed 
Head-
ache, 
Stom-
ach up-
set 
Nausea.  
2. Pulmonary- cox 
3. 
Rifampicin, Etham-
butol, pyra-
zinamide, INH 
4 Macleods 
Hospital	 name:	 DR	 VRK	 Teaching	 Hospital	 &	Reasearch	Hospital	
Address:	Aziz	Nagar,	Moinabad	
Doctor	name:	Dr.	Sreedhar	Reddy	K	
OPD	timing:	10:30am-1:30pm	
Sno. Answer Conclu-sion Adr’s 
1 15-20 
Rifampicin 
is pre-
scribed 
 
Head-
ache, 
Stom-
ach up-
set 
Nausea. 
 
2 Pulmonary 
 
3 
Rifampicin, Etham-
butol, pyrazinamide, 
INH 
4 Sun.pharma 
Hospital	name:	Govt.	General	Hospital	
Address:	Afjal	gaunj,	Hyd	
Doctor	name:	Dr.	Chettra	
OPD	timing:	1pm-4pm	
Sno. Answer Conclu-sion Adr’s 
1. 20-25 
 
Rifam-
picin is 
prescribed 
 
Headache, 
Stomach 
upset, Nau-
sea. 
 
2. Pulmonary 
3. 
Rifampicin, Eth-
ambutol, pyra-
zinamide, INH 
4 Cadila 
Clinic	name:	City	Clinic	&	Diagnostic	Centre	
Address:	Mughalpura,	Hyderabad	
Doctor	name:	Dr.	Omar	Farooq	
OPD	timing:	3pm-6pm	
Sno. Answer Conclusion Adr’s 
1. 5-10  
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2. Pulmonary 
Rifampicin 
is pre-
scribed 
Headache, 
Stomach 
upset 
Nausea. 
 
3. 
Rifampicin, 
Ethambutol, 
pyrazinamide, 
INH 
4 LUPIN 
Hospital	name:	Golconda	TB	unit		
Address:	Golconda,	Hyderabad	
Doctor	name:	Dr.	Maroof	
OPD	timing:	10:00Am-1:00Pm	
Sno. Answer Conclusion Adr’s 
1. 100-110 
Rifampicin 
is prescribed 
Head-
ache, 
Stomach 
upset 
Nausea. 
 
2. Pulmonary 
3. 
Rifampicin,  
Ethambutol, pyra-
zinamide, INH 
4 Sun.pharma 
Hospital	name:	Nampally	TB	Unit	
Address:	Nampally	Market,	Bazar	Ghat	
Doctor	name:	Dr.	Sai	Praveen		
OPD	timing:	10:00Am-1:00Pm	
Sno. Answer Conclu-sion Adr’s 
1. 20-25 
Etham-
butol is 
pre-
scribed 
Heart Burn, Loss 
of Appetite, 
Menstrual 
Changes, Discol-
our of Urine 
2. Pulmonary cox 
3 
Ethambutol, 
Pyra-
zinamide, Ri-
fampicin 
4 Macloid 
Hospital	name:	Shrestha	Hospital	
Address:	Ameerpet	
Doctor	name:	Dr.	Shyamsundar	Raj	
OPD	timing:	10:00Am-1:00Pm	
Sno.	 Answer	 Conclu-sion	 Adr’s	1.	 100-110	
Ethambu-tol	is	pre-scribed	
Heart	Burn,	Loss	of	Appetite,	Men-strual	Changes,	Discolour	of	Urine		
2.	 Pulmo-nary	
3.	
Rifam-picin,	Ethambu-tol,		pyra-zinamide,	INH	4	 Sun	pharma	
Hospital	name:	MM	Hospital	
Address:	Kishanbag	
Doctor	name:	Dr.	Roshan	lal	
OPD	timing:	10:00Am-1:00Pm	
Sno.	 Answer	 Conclusion	 Adr’s	1.	 7-10	 Ethambutol	is	prescribed	 Heart	Burn	Loss	of	Ap-petite	2.	 Pulmonary	3.		 Ethambutol,		
INH,	Pyra-zinamide	 Menstrual	Changes	Discolour	of	Urine	4.	 LUPIN	
	
MARKET	SURVEY	
Pharmacy	Name:	Deluxe	Medical	and	General	Store	
Address:	Dabeerpura,	Hyd	
Pharmacist	Name:	Mohd.	Mustafa	
Sno.	 Answer	 Conclusion	1.	2.	3.	4.	5.	
Cap	R-cin	450mg	Rifampicin	Approximate	 4	brand	R-cin	450mg	Coxid-450mg,	Famcin	450mg		
	As	per	the	pharmacist	Cap.	R-cin	 is	the	most	selling	 brand	 and	 Ri-fampicin	 is	most	 pre-scribed	drug	by	physi-cian	
Pharmacy	Name:	AK	Prince	Pharmacy	
Address:	Dabeerpura,	Hyd	
Pharmacist	Name:	Abdul	Bari	
Sno.	 Answer	 Conclusion	1.	2.	3.		4.	5.	
Cap.	R-cin	450mg	Rifampicin	Approximate	 4	brand	R-cin	450mg	Coxid-450mg,	Famcin	450mg	
	As	per	the	pharmacist	Cap.	R-cin	 is	the	most	selling	 brand	 and	 Ri-fampicin	 is	most	 pre-scribed	drug	by	physi-cian	
Pharmacy	 Name:	 Charminar	 Medical	 and	 General	Store	
Address:	Charminar,	Hyd	
Pharmacist	Name:	Mohd.	Sajjad	
Sno.	 Answer	 Conclusion	1.	2.	3.		4.	5.	
Cap.	R-cin	450mg	Rifampicin	Approximate	 4	brand	R-cin	450mg	Coxid-450mg,	Famcin	450mg		
	As	per	the	pharmacist	Cap.	R-cin	 is	the	most	selling	 brand	 and	 Ri-fampicin	 is	most	 pre-scribed	drug	by	physi-cian	
Pharmacy	Name:	Sunrise	Medical	
Address:	Mughal	pura,	Hyd	
Pharmacist	Name:	Ibrahim	Khan	
Sno. Answer Conclusion 
1. 
2. 
3. 
 
4. 
5. 
Cap R-cin 450mg 
Rifampicin 
Approximate 4 
brand 
R-cin 450mg 
Coxid-450mg, 
Famcin 450mg 
 
As per the pharmacist 
Cap. R-cin is the most 
selling brand and Ri-
fampicin is most pre-
scribed drug by physi-
cian 
Pharmacy	 Name:	 Nizam	 Medical	 Hall	 Chemist	 &	Druggist	
Address:	Mughal	pura,	Hyd	
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Pharmacist	Name:	Fahad		
Sno. Answer Conclusion 1.	2.	3.		4.	5.	
Cap	R-cin	450mg	Rifampicin	Approximate	 4	brand	R-cin	450mg	Coxid-450mg,	Famcin	450mg		
	As	per	the	pharmacist	Cap.	R-cin	 is	 the	most	selling	 brand	 and	 Ri-fampicin	 is	 most	 pre-scribed	drug	by	physi-cian	
Pharmacy	Name:	Ikram	Medical	&	General	Store	
Address:	Etebar	Chowk,	Hyd	
Pharmacist	Name:	Syed	Ikram		
Sno. Answer Conclusion 
1. 
2. 
3. 
 
 
4. 
5. 
Tab.Combutol 
450mg 
Ethambutol 
Approximate 4 brand 
Combutol 450mg 
Albutol 450mg, 
Anbutol 450mg 
 
As per the pharmacist 
Tab. Combutol is the 
most selling brand 
and Ethambutol is 
most prescribed drug 
by physician 
Pharmacy	Name:	Azam	Medical	Hall	&	General	Store	
Address:	Fateh	Darwaza,	Hyd	
Pharmacist	Name:	Abrar	Ali	
Sno. Answer Conclusion 
1. 
2. 
3. 
4. 
5. 
Tab.Combutol 
450mg 
Ethambutol 
Approximate 4 
brand 
Combutol 450mg 
Albutol 450mg, 
Anbutol 450mg 
As per the pharmacist 
Tab. Combutol is the 
most selling brand 
and Ethambutol is 
most prescribed drug 
by physician 
Pharmacy	Name:	Pat	Medical	&	General	Store	
Address:	Bahadur	Pura,	Hyd	
Pharmacist	Name:	Sai	Ram	
Sno. Answer Conclusion 
1. 
2. 
3. 
 
 
4. 
5. 
Tab.Combutol 
450mg 
Ethambutol 
Approximate 4 brand 
Combutol 450mg 
Albutol 450mg, 
Anbutol 450mg 
 
 
As per the pharmacist 
Tab. Combutol is the 
most selling brand 
and Ethambutol is 
most prescribed drug 
by physician 	
RIFAMPICIN	
Sno. Brand (company) Cost 
Generic 
(company) Cost 
1. R cin 450mg (Lupin) 
Rs- 
50/- 
Coxid-
450mg 
(Aristo) 
Rs-
16/- 
2. Macox 450mg (Macleods) 
Rs-
55/- 
Famcin 
450mg 
(IDPL) 
Rs-
17/- 
3. 
Risorine 
450mg 
(Cadila) 
Rs-
60/- 
Rifacept 
450mg 
(Concept) 
Rs-
20/- 
4. Rilfect 400mg (Sun.Pharma) 
Rs-
49/- 
Rifacilin 
450mg 
(PCI) 
Rs-
19/- 
5. 
Eufacin 
450mg 
(Euphoric) 
Rs-
47/- 
Coxkit-3 
450mg 
(Cipla) 
Rs-
12/- 	
ETHAMBUTOL	
Sno. Brand (company) Cost 
Generic 
(company) Cost 
1. 
Combutol 
450mg 
(Lupin) 
Rs-
75/- 
 
Albutol 
450mg 
(Alkem) 
Rs-
25/- 
2. 
Mycobutol 
450mg 
(Cadila ) 
Rs-
86/- 
Anbutol 
450mg 
(Psycorem) 
Rs-
40/- 
3. 
Themibutol 
450mg 
(Themis 
Pharm) 
Rs-
80/- 
Bicox 
450mg 
(Bio E) 
Rs-
42/- 
4. ETOL (sun Pharma) 
Rs69-
/- 
Becox forte 
450mg 
(Panjon) 
Rs-
30/- 
5. ECONEX (Macleod) 
Rs-
70/- 
Caviter-FD 
450mg 
(Wock-
hardt) 
Rs-
35/- 
DISCUSSION	Cost	 effect	 analysis	 is	 the	 study	 for	 providing	 good	therapy	less	adverse	effect	at	low	price,	We	choose	TB	for	Pharmacoeconomic	study	because	TB	need	 long	term	drug	treatment	approximately	for	2	years	 it	 is	expensive	 for	patient,	TB	 is	 the	most	 infectious	dis-ease	 killer	 in	 the	world,	We	 conducted	 clinical	 and	market	survey,	As	per	clinical	survey	69%	of	physi-cians	have	faith	on	Rifampicin	and	20%	on	Ethambu-tol	and	Remaining	11%	are	multidrug	therapy.	
 
Figure 1: Pie diagram for clinical survey of TB drugs	
SUMMARY	Pharmacoeconomic	study	means	cost	effective	analy-sis,	TB	is	a	top	infectious	disease,	killer	in	the	world,	10.4	million	people	suffer	from	TB	every	year,	1.7	mil-lion	people	die	from	TB,	Each	day	4700	people	lose	their	life	and	28500	people	fall	ill	due	to	TB,	Cost	to	cost,	 efficacy	 to	 efficacy	 in	 between	 most	 popular	
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anti-tubercular	brands	present	in	market,	For	Phar-macoeconomic	study	we	have	done	clinical	survey	as	well	as	market	survey.	
 
Figure 2: Bar diagram for clinical survey of TB drugs	
Clinical	 survey:	Targeted	TB	 hospitals,	 Demand	 of	product,	Physician	faith	on	brand/drug	Approximately	per	week	240	TB	infected	patients	are	diagnose	in	TB	center	in	which	pulmonary	TB	patient	80%	and	20%	of	patient	with	extra	pulmonary.	
Market	survey:	Retail	outlet	 in	TB	center	and	Out-side	the	TB	center,	Reliable	brands	as	well	as	low	cost	brands,	Questions	to	retailer,	collecting	retailer	data	
CONCLUSION	As	we	know	that	TB	is	most	infectious	disease	cause	by	Mycobacterium	Tuberculosis	it	mainly	affects	the	respiratory	 tract.	As	per	 clinical	and	market	 survey	we	 found	 that	 Rifampicin	 is	 most	 trusted	 anti-TB	drug	and				R-cin450	was	found	to	be	most	prescribed	and	selling	brand	in	the	market.	Rifampicin	occupies	69%	in	the	market.	Ethambutol	occupies	20%	in	the	market.	Other	anti-TB	drug	occupy	11%	in	the	mar-ket.	Rifampicin	has	less	ADR	and	it	is	most	prescribed	drug	as	compared	 to	Ethambutol.	We	can	minimize	the	cost	by	prescribing	generic	drug.	Rifampicin	has	less	ADR	(headache,	stomach	upset,	nausea,	vomiting,	dizziness)	 as	 compare	 to	 Ethambutol	 ADR	 (heart	burning,	 loss	 of	 appitite,	 menstrual	 changes,	 urine	discolour).	We	can	change	reduce	the	cost	of	anti-TB	therapy	by	using	 generic	 drugs	 at	 the	place	 of	 pre-scribed	 brand.	 Because	 generic	 drug	 are	 approxi-mately	60%	less	in	cost	than	other	branded	drugs.	
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